Overview

Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites

Status:
Terminated
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Peritoneal infusion of heated chemotherapy drugs, such as mitomycin, may kill more tumor cells. PURPOSE: This phase II trial is studying how well mitomycin works when given as a hyperthermic peritoneal perfusion in treating patients with malignant ascites.
Phase:
Phase 2
Details
Lead Sponsor:
Masonic Cancer Center, University of Minnesota
Treatments:
Mitomycin
Mitomycins